Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Enoblituzumab · MGA-271

Monoclonal antibody · Kills target cells, directed at B7-H3 (CD276) · developed by MacroGenics

Being checked. Our sources disagree on some details of this drug, so parts of this page may be wrong until a person has reviewed it.
Phase 2 Most advanced trial
MGNX Developer
3 Registered trials

What is Enoblituzumab?

Enoblituzumab is a humanized monoclonal antibody with an Fc domain optimized for effector function, directed against cancer stem cells and differentiated tumor cells. It binds B7-H3, a protein expressed on tumor cells, and may induce antibody-dependent cell-mediated cytotoxicity against these cells. It is studied in prostate cancer, melanoma, head and neck cancer, non-small cell lung cancer and urothelial carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MGA-271
Drug type
Monoclonal antibody
Targets
B7-H3 (CD276)
Mechanism
Kills target cells, directed at B7-H3 (CD276)
Pathways
antibody-dependent cell-mediated cytotoxicity
Therapy area
Oncology
Developer
MacroGenics (MGNX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
M6030H73N9

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06014255 Phase 2 Prostate Cancer Active not recruiting MGNX
NCT02475213 Phase 1 Melanoma Completed MGNX
NCT01918930 Phase 1 Melanoma Terminated MGNX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Prostate CancerHead and Neck CancerMelanomaNon Small Cell Lung CancerUrothelial Carcinoma

Other drugs acting on CD276

More from MacroGenics

Sources

Updated Nov 22, 2026. Something wrong or missing? Report it on the MGNX page.

Follow MGNX, the company behind Enoblituzumab

See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MGNX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.